Download PDF
Open Access
Thromb Haemost 1977; 38(01): 96
DOI: 10.1055/s-0039-1680568
Mixed Posters IV
Platelets
F.K. Schattauer Verlag

Evaluation of the Antithrombotic Properties of Suloctidil in Patients with Substitute Heart Valves

Authors

  • M. Moriau

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • A. Ferrant

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • C. Col-De Beys

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • A. Hurlet

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • C. Chalant

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • R. Ponlot

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • P. Jaumain

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • M. Goenen

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium

  • R. Masure

    1   Haemostasis and Thrombosis Research Unit, University of Louvain, Belgium
Further Information

Publication History

Publication Date:
16 April 2019 (online)

 
 PDF Download Permissions and Reprints

    Isotopic platelet survival time (PST), platelet count, adhesiveness, aggregation, PF4 release and coagulation parameters were examined in 23 patients with prosthetic heart valves (6 mitral, 10 aortic and 7 mitroaortic Starr Edwards or Bjork valves) treated with or without suloctidil.

    The patients were distributed in 2 comparative groups : the treated group with 11 patients with VKA (nicoumalone) and suloctidil (600 mg/day) and the control group with 12 patients with VKA alone. The biological parameters were performed before (the 10th postop. day) and 6 weeks after treatment with or without suloctidil.

    Before treatment were : PST shortened, platelet adhesiveness and aggregation normal and PF4 release, factors I, VIII-C, VIII-R-Ag increased in both groups.

    After treatment, PST returned to normal in the treated group, but remained unchanged or was more decreased in the control group. Platelet adhesiveness and aggregation were unchanged in both groups. PF4 release was reduced in the treated group and unchanged in the control group. Platelet count, factors I, VIII-C, VIII-R-Ag returned to the preoperative values in both groups.

    Two severe thromboembolic complications appeared in the control group, none in the treated group.


     

     


     
      Permissions and Reprints